NDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting ...
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug ...
The Food and Drug Administration approved the first new drug in over 30 years to treat schizophrenia in adults. The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers Squibb, ...
In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...
LOS ANGELES — The novel phosphodiesterase 10A (PDE10A) inhibitor known as CPL'36 (Celon Pharma) is effective and generally safe in acute exacerbations of schizophrenia, new research suggested. In a ...
Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia, saying the treatment is effective without the ...
Caplyta (lumateperone) is a prescription drug used to treat schizophrenia in adults. It does not come as a generic drug. Caplyta comes as an oral capsule. The active ingredient in Caplyta is ...
Abstract and Introduction Clinical Profile of Aripiprazole as Reflected by Clinical Trial Data Use of Aripiprazole in the Treatment of Schizophrenia: Consensus Report Conclusion References Control of ...
Russia is facing a shortage of drugs which are used for the treatment of schizophrenia, psychosis, bipolar disorder, and ...
Everyday Health on MSN
Restoring intimacy: Navigating sexual dysfunction in schizophrenia and your treatment options
Sexual dysfunction is a common side effect of antipsychotics, but it doesn’t have to be permanent. Learn about causes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results